First Annual NYC CLL Consortium Meeting

First Annual NYC Chronic Lymphocytic Leukemia (CLL) Consortium Meeting is organized by Melton Medical Education, LLC and will be held on Feb 05, 2027 at CUNY Graduate Center, New York, New York, United States of America.

Description:
The NYC CLL Consortium Meeting is a premier annual educational forum dedicated to advancing the management of chronic lymphocytic leukemia (CLL). Led by investigators from the NYC CLL Consortium, the inaugural program brings together academic and community hematologists/oncologists, fellows, advanced practice providers, and multidisciplinary clinicians involved in CLL research and care.

Meeting Highlights:
• Latest biologic discoveries, translational insights, and pivotal clinical trial data

• Collaboration among leading CLL experts and institutions

• Practical strategies for integrating emerging therapies into real-world practice

• Discussion and expert interpretation of the latest data presented at ASH

Why Attend:
CLL management is evolving rapidly - with the rise of combination treatment strategies, an expanding interplay between clinical trial findings and community practice, an aging patient population, and the emergence of novel therapeutics. This meeting is designed to help clinicians stay ahead of these changes.

Join leading experts as they translate the latest science into actionable clinical insights. Attendees will gain practical tools and confidence to implement evolving treatment approaches and optimize patient outcomes across both academic and community care settings.

Learning Objectives:
Upon completion of this educational activity, learners should be better able to:

• Interpret current and emerging biologic, translational, and clinical evidence to guide CLL treatment decisions. 
• Apply risk stratification and patient-specific factors to develop individualized treatment plans. 
• Evaluate and integrate clinical trial data on combination strategies, and provide guidance on implementing novel therapeutics into practice. 
• Implement evidence-based monitoring and toxicity management strategies for novel CLL therapies. 
• Collaborate across care teams to coordinate safe and effective implementation of novel CLL therapies in diverse urban practice settings.